- 1.
Cameron F, Whiteside G, Perry C. Ipilimumab: first global approval. Drugs 2011; 71: 1093–104. [PubMed][CrossRef]
- 2.
Haslam A, Prasad V. Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs. JAMA Netw Open 2019; 2: e192535. [PubMed][CrossRef]
- 3.
INSPIRE. lungekreft. Evaluering av pilotprosjekt. Oslo: Kreftregisteret, 2021. https://www.kreftregisteret.no/globalassets/ publikasjoner-og-rapporter/inspire/inspire_lungekreft_evaluering-av-pilotprosjekt.pdf Lest 10.3.2022.
- 4.
Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science 2018; 359: 1350–5. [PubMed][CrossRef]
- 5.
Sury K, Perazella MA, Shirali AC. Cardiorenal complications of immune checkpoint inhibitors. Nat Rev Nephrol 2018; 14: 571–88. [PubMed][CrossRef]
- 6.
Mahmood SS, Fradley MG, Cohen JV et al. Myocarditis in Patients Treated With Immune Checkpoint Inhibitors. J Am Coll Cardiol 2018; 71: 1755–64. [PubMed][CrossRef]
- 7.
Johnson DB, Sullivan RJ, Ott PA et al. Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders. JAMA Oncol 2016; 2: 234–40. [PubMed][CrossRef]
- 8.
Salem JE, Manouchehri A, Moey M et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol 2018; 19: 1579–89. [PubMed][CrossRef]
- 9.
Escudier M, Cautela J, Malissen N et al. Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor-Related Cardiotoxicity. Circulation 2017; 136: 2085–7. [PubMed][CrossRef]
- 10.
Zhang L, Zlotoff DA, Awadalla M et al. Major Adverse Cardiovascular Events and the Timing and Dose of Corticosteroids in Immune Checkpoint Inhibitor-Associated Myocarditis. Circulation 2020; 141: 2031–4. [PubMed][CrossRef]
- 11.
Ragnum HB, De Bortoli AM, Elsais A et al. En mann i 60-årene med dyspné etter immunterapi. Tidsskr Nor Legeforen 2021; 141. doi: 10.4045/tidsskr.21.0139. [CrossRef]
- 12.
Karlsen TLS, Karlsen J, Mo R et al. En kvinne i 80-årene med brystsmerter under immunterapi mot melanom. Tidsskr Nor Legeforen 2021; 141. doi: 10.4045/tidsskr.20.0982. [CrossRef]
- 13.
Hu JR, Florido R, Lipson EJ et al. Cardiovascular toxicities associated with immune checkpoint inhibitors. Cardiovasc Res 2019; 115: 854–68. [PubMed][CrossRef]
- 14.
Johnson DB, Balko JM, Compton ML et al. Fulminant Myocarditis with Combination Immune Checkpoint Blockade. N Engl J Med 2016; 375: 1749–55. [PubMed][CrossRef]
- 15.
Lyon AR, López-Fernández T, Couch LS et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J 2022; 43: 4229–361. [PubMed][CrossRef]
- 16.
Ferreira VM, Schulz-Menger J, Holmvang G et al. Cardiovascular Magnetic Resonance in Nonischemic Myocardial Inflammation: Expert Recommendations. J Am Coll Cardiol 2018; 72: 3158–76. [PubMed][CrossRef]
- 17.
Thavendiranathan P, Zhang L, Zafar A et al. Myocardial T1 and T2 Mapping by Magnetic Resonance in Patients With Immune Checkpoint Inhibitor-Associated Myocarditis. J Am Coll Cardiol 2021; 77: 1503–16. [PubMed][CrossRef]
- 18.
Zhang L, Awadalla M, Mahmood SS et al. Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis. Eur Heart J 2020; 41: 1733–43. [PubMed][CrossRef]
- 19.
Thuny F, Alexandre J, Salem JE et al. Management of Immune Checkpoint Inhibitor-Induced Myocarditis: The French Working Group's Plea for a Pragmatic Approach. JACC CardioOncol 2021; 3: 157–61. [PubMed][CrossRef]
- 20.
Moslehi JJ, Salem JE, Sosman JA et al. Reporting of immune checkpoint inhibitor-associated myocarditis - Authors' reply. Lancet 2018; 392: 384–5. [PubMed][CrossRef]
- 21.
US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. https:// ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf Lest 3.3.2022.
- 22.
Pudil R, Mueller C, Čelutkienė J et al. Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology. Eur J Heart Fail 2020; 22: 1966–83. [PubMed][CrossRef]
- 23.
Matzen E, Bartels LE, Løgstrup B et al. Immune checkpoint inhibitor-induced myocarditis in cancer patients: a case report and review of reported cases. Cardiooncology 2021; 7: 27. [PubMed][CrossRef]
- 24.
Global cardio-oncology summit 2021. Videokonferanse. Session 7 - "How do I…" Fireside Chats. https://wondrmedical.net/ch/ICOS/events/Gcos-2021-Virtual Lest 26.2.2022 Lest 3.3.2022.
()